Satellos Bioscience Inc
MSCL
Company Profile
Business description
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
Contact
200 Bay Street
Suite 2800, Royal Bank Plaza, South Tower
TorontoONM5J 2J1
CANT: +1 905 336-6128
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.70 | 38.20 | 0.43% |
| CAC 40 | 8,135.03 | 35.06 | -0.43% |
| DAX 40 | 23,730.66 | 145.89 | -0.61% |
| Dow JONES (US) | 47,147.48 | 309.74 | -0.65% |
| FTSE 100 | 9,679.23 | 19.14 | -0.20% |
| HKSE | 26,384.28 | 188.18 | -0.71% |
| NASDAQ | 22,900.59 | 30.23 | 0.13% |
| Nikkei 225 | 50,323.91 | 52.62 | -0.10% |
| NZX 50 Index | 13,499.04 | 34.58 | 0.26% |
| S&P 500 | 6,734.11 | 3.38 | -0.05% |
| S&P/ASX 200 | 8,636.40 | 32.30 | 0.38% |
| SSE Composite Index | 3,972.03 | 18.46 | -0.46% |